PURPOSE: The purpose of this article was to develop, characterize and test (in vivo) dacarbazine microparticles that may be labeled with 99mTc and Ra-223 for both use: diagnostic and therapy of metastatic melanoma. METHODS: We developed by double emulsion solvent evaporation methodology the microparticle. The characterization has been done using, Dynamic Light Scattering (DLS) and Scanning Electron Microscopy (SEM). The labeling with 99mTc and Ra-223 has been done by the direct labeling process. Also the formulation has been tested pre-clinically using Balb/c mice inducted with melanoma, performing the the biodistribution and planar imaging. Cytotoxicity evaluation was also done in M3 V cell line. In order to understand the safety aspects of the microparticles, microbiological study (endotoxin and sterility) has been done. Finally, planar imaging was performed to evaluate the diagnosing aspect. RESULTS: The results showed that a 559 nm microparticles was obtained with a spherical shape. The labeling process with 99mTc reached over 90% of efficacy. On the other hand, the labeling process with Ra-223 showed a 70% efficacy. The results in inducted animals demonstrated that the microparticles were able to reach the tumor with a high rate (20%). Also demonstrated a low recognition by the Mononuclear Phagocytic System. The cytotoxicity and the microbiological control, corroborates the safety aspect of these microparticles. CONCLUSION: The planar image and the possible labeling with Ra-223, corroborates the use as a theragnostic agent for imaging and therapy of Metastatic Melanoma.

Brazilian Nuclear Energy Commission Nuclear Engineering Institute Rio de Janeiro Brazil

Centro de Radiofarmácia Instituto de Pesquisas Energéticas e Nucleares São Paulo Brazil

Cyclotron and Radiopharmaceuticals Department King Faisal Specialist Hospital and Research Center Riyadh Saudi Arabia

Faculty of Pharmaceutical Sciences University of São Paulo São Paulo SP Brazil

Faculty of Pharmacy Federal University of Rio de Janeiro Rio de Janeiro Brazil

Katedra jaderné chemie FJFI ČVUT Praha Prague Czech Republic

Laboratory of Molecular and Cellular Pharmacology; Department of Cell Biology Institute of Biology Roberto Alcântara Gomes Biomedical Center State University of Rio de Janeiro Rio de Janeiro RJ Brazil

See more in PubMed

J Clin Pathol. 2004 Aug;57(8):797-801 PubMed

Mayo Clin Proc. 2006 Apr;81(4):511-6 PubMed

Br J Dermatol. 2007 Dec;157 Suppl 2:47-51 PubMed

Small. 2010 Dec 6;6(23):2678-82 PubMed

Expert Rev Anticancer Ther. 2010 Nov;10(11):1811-23 PubMed

Photochem Photobiol Sci. 2012 Jan;11(1):191-8 PubMed

Saudi Pharm J. 2012 Oct;20(4):331-44 PubMed

PLoS One. 2014 Jun 09;9(6):e99481 PubMed

Nucl Med Biol. 2014 Oct;41(9):772-4 PubMed

Int J Cancer. 2015 Mar 1;136(5):E359-86 PubMed

CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29 PubMed

Cir Cir. 2015 Mar-Apr;83(2):175-80 PubMed

Nanomedicine (Lond). 2015;10(16):2613-33 PubMed

Aust Prescr. 2015 Jun;38(3):74-8 PubMed

Medicine (Baltimore). 2016 Apr;95(16):e3406 PubMed

Am Health Drug Benefits. 2016 Jun;9(4):203-13 PubMed

Chonnam Med J. 2016 Sep;52(3):185-93 PubMed

Pigment Cell Melanoma Res. 2017 Mar;30(2):233-242 PubMed

J Clin Oncol. 2017 Mar;35(7):705-708 PubMed

Curr Oncol. 2016 Dec;23(6):e563-e570 PubMed

Cancer Immunol Immunother. 2017 May;66(5):647-656 PubMed

Chin J Cancer. 2017 Jan 13;36(1):10 PubMed

Clin Cancer Res. 2017 Jul 15;23(14):3484-3488 PubMed

Immunotargets Ther. 2017 Feb 13;6:1-10 PubMed

BMC Med. 2017 Mar 17;15(1):57 PubMed